论文部分内容阅读
目的观察格列美脲联合预混胰岛素治疗2型糖尿病(type 2 diabetes mellitus,T2DM)的临床效果。方法选择2011年12月—2012年6月收治的使用次大剂量(40～60 U/d)预混胰岛素治疗血糖未达标[糖化血红蛋白(hemoglobinA1c,HbA1c)>7.0%]的T2DM患者100例,随机分为治疗组和对照组各50例,均给予强化治疗,治疗组加用格列美脲,3个月后比较两组HbA1c、胰岛素用量。结果 3个月后HbA1c水平较基线治疗组降低了(2.02±1.09)%,对照组降低了(1.76±0.74)%;血糖达标率分别为78%和69%;在达标患者中治疗组的胰岛素用量减少(12.32±3.26)U,而对照组减少(7.67±2.20)U。两组比较差异均有统计学意义(均P<0.05)。结论格列美脲作为一种口服降糖药物可以联合预混胰岛素治疗,有利于实现血糖控制达标,同时可以节省外源性胰岛素用量,并且不增加降糖治疗费用,可作为T2DM使用胰岛素患者的很好选择。
Objective To observe the clinical efficacy of glimepiride combined with premixed insulin in treatment of type 2 diabetes mellitus (T2DM). Methods A total of 100 patients with T2DM undergoing sub-maximal dose (40-60 U / d) of premixed insulin for treatment of non-compliance of blood glucose (hemoglobin A1c> 7.0%) were enrolled from December 2011 to June 2012, Randomly divided into treatment group and control group of 50 cases, were given intensive treatment, the treatment group with glimepiride, three months later compared the two groups HbA1c, insulin dosage. Results After 3 months, the HbA1c level was decreased by 2.02 ± 1.09% compared with that of the baseline treatment group and 1.76 ± 0.74% by the control group. The blood glucose compliance rates were 78% and 69% respectively. The insulin levels The dosage decreased (12.32 ± 3.26) U, while the control group decreased (7.67 ± 2.20) U. The differences between the two groups were statistically significant (P <0.05). Conclusion Glimepiride, as an oral hypoglycemic agent, can be used in combination with premixed insulin therapy to achieve glycemic control standard while saving exogenous insulin dose without increasing the cost of hypoglycemic therapy and can be used as an insulin in T2DM patients Very good choice.